RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by West China Hospital; 3 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 4

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorWest China Hospital四川大学华西医院ChengduHospital page
  2. Study siteAffiliated Hospital of North Sichuan Medical College川北医学院附属医院NanchongHospital page
  3. Study siteAffiliated Hospital of Southwest Medical University西南医科大学附属医院LuzhouHospital page
  4. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07855965, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).

    Inclusion criterion 2

    The primary lung lesion must be technically amenable to percutaneous biopsy and CT-guided Cryo-Thermal Ablation..

    Inclusion criterion 6

  3. Clinical stage IB-IIIB according to the 9th edition IASLC/AJCC TNM classification.

    Inclusion criterion 3

    For stage IB disease, only patients with a maximum tumor diameter of 4.0 cm (cT2aN0M0) are eligible.

    Inclusion criterion 4

  4. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception from enrollment until at least 180 days after the last dose of study systemic therapy.

    Inclusion criterion 27

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    Inclusion criterion 10

  6. Hemoglobin ≥9.0 g/dL;

    Inclusion criterion 17

    absolute neutrophil count ≥1.0 × 10⁹/L;

    Inclusion criterion 18

    platelet count ≥90 × 10⁹/L;

    Inclusion criterion 19

    total bilirubin ≤2.0 × upper limit of normal (ULN);

    Inclusion criterion 20

    alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤2.5 × ULN;

    Inclusion criterion 21

    serum creatinine ≤2.0 mg/dL and creatinine clearance ≥60 mL/min;

    Inclusion criterion 22

    international normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 × ULN, unless abnormalities are attributable to protocol-permitted anticoagulation.

    Inclusion criterion 24

    EGFR sensitizing or protocol-defined activating alterations, including exon 19 deletion, L858R, G719X, S768I, L861Q, or exon 20 insertion;

    Exclusion criterion 4

  7. Small-cell lung cancer (SCLC) or mixed histology containing a small-cell component.

    Exclusion criterion 2

    Active tuberculosis or inadequately controlled tuberculosis treated within 1 year before enrollment.

    Exclusion criterion 30

    Active hepatitis B infection with HBV DNA above the protocol-defined acceptable limit.

    Exclusion criterion 32

    Active hepatitis C infection with detectable HCV RNA.

    Exclusion criterion 33

    Another malignancy diagnosed within 2 years before enrollment, except malignancies with a negligible risk of metastasis or death that have been adequately treated, such as basal cell or squamous cell carcinoma of the skin or carcinoma in situ treated with curative intent.

    Exclusion criterion 40

    Receipt of anti-cancer traditional Chinese patent medicines or systemic immunomodulatory agents, including thymosin, interferons, or interleukins, within 2 weeks before initiation of study treatment.

    Exclusion criterion 43

  8. Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (HCG) pregnancy test within 7 days before initiation of study treatment.

    Inclusion criterion 26

    Pregnancy, Lactation, and Transplantation

    Exclusion criterion 45

    Pregnancy or breastfeeding.

    Exclusion criterion 46

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07855965, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria

  • Diagnosis, Stage, and Resectability
  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
  • Clinical stage IB-IIIB according to the 9th edition IASLC/AJCC TNM classification.
  • For stage IB disease, only patients with a maximum tumor diameter of 4.0 cm (cT2aN0M0) are eligible.
  • The disease must be considered resectable by multidisciplinary team (MDT) assessment with curative-intent surgery planned after neoadjuvant treatment.
  • The primary lung lesion must be technically amenable to percutaneous biopsy and CT-guided Cryo-Thermal Ablation..
  • No prior systemic or local anti-tumor therapy for the current NSCLC.
  • Age, Performance Status, and General Condition
  • Age 18-80 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Estimated life expectancy >6 months.
  • Able to understand and voluntarily sign the informed consent form and willing to comply with study treatment, specimen collection, and follow-up requirements.
  • Tumor Tissue and Pulmonary Function
  • Willing to provide tumor tissue and blood samples required by the study protocol.
  • Adequate pulmonary function for the planned treatment and subsequent pulmonary resection, including: FEV1 ≥1.2 L or ≥50% of predicted value; and predicted postoperative FEV1≥30% of predicted value.
  • Adequate Organ Function

Laboratory assessments performed within 7 days before the first study intervention must meet the following criteria:

  • Hemoglobin ≥9.0 g/dL;
  • absolute neutrophil count ≥1.0 × 10⁹/L;
  • platelet count ≥90 × 10⁹/L;
  • total bilirubin ≤2.0 × upper limit of normal (ULN);
  • alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤2.5 × ULN;
  • serum creatinine ≤2.0 mg/dL and creatinine clearance ≥60 mL/min;
  • adequate thyroid function. If thyroid-stimulating hormone (TSH) is outside the normal range, free T3 and free T4 must be within clinically acceptable limits; no clinically significant abnormality in cardiac enzyme testing;
  • international normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 × ULN, unless abnormalities are attributable to protocol-permitted anticoagulation.
  • Reproductive Requirements
  • Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (HCG) pregnancy test within 7 days before initiation of study treatment.
  • Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception from enrollment until at least 180 days after the last dose of study systemic therapy.

Exclusion Criteria

  • Histological or Molecular Characteristics
  • Small-cell lung cancer (SCLC) or mixed histology containing a small-cell component.
  • Presence of protocol-defined actionable oncogenic alterations detected by tumor tissue and/or plasma-based molecular testing, including:
  • EGFR sensitizing or protocol-defined activating alterations, including exon 19 deletion, L858R, G719X, S768I, L861Q, or exon 20 insertion;
  • ALK rearrangement;
  • ROS1 rearrangement;
  • MET exon 14 skipping alteration or protocol-defined MET amplification;
  • KRAS G12C;
  • BRAF V600E;
  • NTRK1/2/3 fusion;
  • RET rearrangement; or HER2 alteration as defined in the study protocol.
  • Contraindications to Percutaneous Biopsy or Cryo-Thermal Ablation
  • Active clinically significant hemoptysis, defined as ≥1/2 teaspoon of fresh blood, within 2 weeks before the planned procedure.
  • Clinically significant bleeding tendency or coagulation disorder that cannot be adequately corrected before biopsy or ablation.
  • Therapeutic anticoagulant or vitamin K antagonist treatment that cannot be safely interrupted or managed during the periprocedural period according to the study protocol and institutional practice. Stable anticoagulation may be permitted when appropriate periprocedural interruption or management is considered safe by the investigator.
  • Active infection involving the planned biopsy or ablation site or access pathway.
  • Any anatomical or clinical condition considered by the investigator to make percutaneous biopsy or combined Cryo-Thermal Ablation unsafe.
  • Clinically Significant Cardiovascular or Systemic Disease
  • Uncontrolled hypertension.
  • Unstable angina, myocardial infarction within 3 months before enrollment, New York Heart Association (NYHA) class II or higher heart failure considered clinically significant by the investigator, or severe/uncontrolled arrhythmia.
  • Severe or uncontrolled hepatic, renal, metabolic, or other systemic disease that could interfere with study treatment or assessment.
  • Immunotherapy-Related Contraindications
  • Active or suspected autoimmune disease requiring systemic treatment, except for conditions permitted by the protocol, such as vitiligo, type 1 diabetes mellitus, or adequately controlled autoimmune hypothyroidism.
  • History of autoimmune disease requiring systemic treatment with disease-modifying agents, corticosteroids, or immunosuppressive therapy within 2 years before enrollment, except as specifically permitted by the protocol.
  • Requirement for chronic systemic immunosuppressive treatment.
  • Systemic glucocorticoid treatment within 7 days before initiation of systemic study treatment, except physiologic replacement therapy equivalent to prednisone ≤10 mg/day.
  • Uncontrolled peripheral neuropathy of grade ≥2 or other condition that, in the investigator's judgment, would substantially increase the risk of study treatment.
  • Psychiatric, cognitive, or other conditions that would prevent adequate informed consent or compliance with study procedures.
  • Active or Clinically Significant Infection
  • Active tuberculosis or inadequately controlled tuberculosis treated within 1 year before enrollment.
  • Human immunodeficiency virus (HIV) infection with clinically significant immunodeficiency or acquired immunodeficiency syndrome (AIDS), as defined by the study protocol.
  • Active hepatitis B infection with HBV DNA above the protocol-defined acceptable limit.
  • Active hepatitis C infection with detectable HCV RNA.
  • Other uncontrolled active infection requiring systemic therapy that, in the investigator's judgment, would interfere with study treatment.
  • Pulmonary Conditions
  • Interstitial lung disease, interstitial pneumonia, pneumoconiosis, drug-induced pneumonitis, or other clinically significant diffuse pulmonary disease that may increase the risk of study treatment.
  • Severe impairment of pulmonary function incompatible with the planned ablation, systemic therapy, or subsequent surgical resection.
  • Clinically uncontrolled pleural or pericardial effusion. Participants whose effusion is adequately controlled and clinically stable after drainage may be eligible according to investigator assessment and the study protocol.
  • Other Malignancies
  • Another malignancy diagnosed within 2 years before enrollment, except malignancies with a negligible risk of metastasis or death that have been adequately treated, such as basal cell or squamous cell carcinoma of the skin or carcinoma in situ treated with curative intent.
  • Concurrent or Recent Treatments
  • Participation in another interventional clinical trial or receipt of another investigational drug or investigational device within 4 weeks before the first study intervention.
  • Receipt of anti-cancer traditional Chinese patent medicines or systemic immunomodulatory agents, including thymosin, interferons, or interleukins, within 2 weeks before initiation of study treatment.
  • Receipt of a live attenuated vaccine within 30 days before initiation of study treatment. Inactivated vaccines, including inactivated influenza vaccines, are permitted.
  • Pregnancy, Lactation, and Transplantation
  • Pregnancy or breastfeeding.
  • Unwillingness to comply with protocol-specified contraceptive requirements.
  • Previous organ or bone marrow transplantation, or planned transplantation during the study period.
  • Other Exclusion Criteria
  • Known severe hypersensitivity or contraindication to toripalimab, protocol-specified chemotherapy agents, their excipients, or materials used in the ablation procedure.
  • Any other medical, psychological, social, or logistical condition that, in the investigator's judgment, makes the participant unsuitable for study enrollment or could interfere with treatment safety, protocol compliance, or interpretation of study results.

Quoted from ClinicalTrials.gov, NCT07855965, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07855965, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07855965